BioCentury | Jun 27, 2019
Product Development
Gene therapy’s next frontier lies beyond rare, monogenic diseases
As in vivo gene therapies continue notching approvals for rare monogenic diseases, the next frontier for the modality will be in treating complex indications without obvious genetic drivers. At least seven companies have clinical or...